Glaucoma is a complicated disease in which damage to the optic nerve leads to progressive, irreversible vision loss. The LondonOC (The London Ophthalmology Centre) is now offering the most innovative treatment available today — XEN Gel Implants.
The prominent ophthalmology clinic is situated in the heart of London's world famous medical district — and is providing comprehensive care for patients all over the world.
Ophthalmologic Studies Center of Saltillo
Professional Ophthalmology - Dr. Adolfo Pena Aceves
The London Ophthalmology Centre (LondonOC)
The VisitandCare.com partnered laser eye surgery provider is excited about the progress of new surgical options for glaucoma, and the tools and techniques for managing the disease. Beyond its innovative glaucoma treatment, the premier ophthalmology center in the UK offers cataract surgery, LASIK eye surgery, cosmetic eyelid surgery, pterygium surgery, and facial aesthetics.
Facts — Four Key Facts on Glaucoma
Glaucoma is a leading cause of blindness. Glaucoma can cause blindness if it is left untreated. Nearly 10 percent of individuals who receive treatment still experience loss of vision.
The Fight Continues. Glaucoma is not curable, and vision lost cannot be regained — but researchers are continually searching for a cure. Glaucoma management has evolved rapidly in the last five years and we now have the capability to stop and prevent any further damage to the nerve, and your sight.
Everyone is at risk for glaucoma. From newborns to seniors, everyone is at risk for glaucoma. African Americans in particular are susceptible at a younger age.
There may be no symptoms. With open-angle glaucoma, there are virtually no symptoms. Usually, no pain is associated with increased eye pressure. Vision loss begins with peripheral or side vision. The best way to protect your sight from glaucoma is to get tested.
Innovation — XEN Gel Stent Implant
AqueSys, Inc. is the first ophthalmic device company to focus exclusively on the treatment of glaucoma. Backed by more than a decade of research and commercialization in European and Canadian markets, the company’s newest technology supports glaucoma surgeons and patients in the management of intraocular pressure.
The innovative procedure at LondonOC uses a 6mm implant designed to deliver significant IOP control, and reduce the risk of further vision loss. Surgeons at the laser eye surgery clinic in London create a permanent pathway to reduce the amount of fluid in the eye. This helps preserve vision by reducing the pressure in the eye to a normal level.
“The past year has seen tremendous commercial and clinical development in the use of XEN for the control of IOP and the World Glaucoma Congress affords an excellent opportunity to present the latest information, data and techniques to those on the frontline of glaucoma management,” stated Ron Bache, CEO of AqueSys, Inc. “The panel hosting the XEN Gel Stent Symposium will offer their first-hand knowledge and expert insights in the use of this advanced device, providing a new point of intervention in the disease progression.”